Paxlovid may offer marginal benefits for low-risk children with COVID-19; however, among high-risk children with COVID-19, Paxlovid is a safe oral option.

Paxlovid vs placebo reduced COVID-19-related hospitalization and death due to any cause through 28 days, as well as the duration of COVID-19 symptoms.

Dexamethasone reduced mortality among patients hospitalized with COVID-19, especially those who were also receiving respiratory support.

The FDA has approved Journavx, a pain medication, offering a safer alternative to opioids. Learn about its benefits and side effects.

The nonaddictive painkiller suzetrigine (Journavx) is as effective for acute pain as a common opioid treatment ...

Who’s at the peak? COVID-19 has hit some countries far harder than others, though differences in the way infections are counted locally make it impossible to make a perfect apples-to-apples ...

The FDA has approved a new type of painkiller that doesn't come with the risks of addiction and overdose associated with opioids.

Using glucocorticoids, rituzimab, or certain immunosuppressants to treat connective tissue diseases is associated with greater risks for severe COVID-19-related outcomes.